“This study will provide us additional valuable information regarding the optimum dose range for testosterone suppression, an important outcome measure in the management of hormone-dependent prostate cancer,” stated Dr Rajesh Shrotriya, chairman of the board, CEO and president of Spectrum Pharmaceuticals.
Prostate cancer is the second leading cause of cancer deaths in men and occurs when a malignant tumor forms in the tissue of the prostate. According to figures released by the American Cancer Society, approximately 232,090 new cases and 30,350 deaths will occur in the US during 2005.
Ozarelix is also currently in two European trials.